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Available online 16 March 2016Background: Adult granulosa cell tumor of the ovary (AGCT) is a rare functional sex-cord-stromal ovarian
neoplasm characterized by low malignant potential and late relapse. Evidence-based management options for
women with recurrent AGCT are limited.
Case report:We present the case of a 60-year-old woman with the ﬁfth recurrence of AGCT initially diagnosed
19 years ago. After initial surgery in 1996, the patient underwent four additional surgical interventions for recurrent
disease in 2005 (abdominal wall), 2009 (abdominal wall), 2010 (paravesical), and 2011 (paravesical). In 2011, she
underwent pelvic irradiation with 50.5 Gray. In 2015, another recurrence was diagnosed based on an increase of
serum inhibin and a tumor seen on CT scan in the right upper abdomen. The patient underwent cytoreductive
surgery (CRS) with complete cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
with cisplatin 50 mg/m2 and doxorubicin 15 mg/m2. No intra- or post-operative complications occurred. Final
histology revealed recurrent AGCT with 6 cm in the largest diameter. Subsequently, antihormonal treatment with
anastrozole 1.5 mg per day was prescribed. With a follow-up of six months, the patient is well and alive.
Conclusion:CRS andHIPEC are a reasonable treatment option for selectedwomenwith recurrentAGCT limited to the
abdomen.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Ovarian neoplasma1. Introduction
Sex-cord-stromal tumors are rare ovarian neoplasms accounting for
less than 5% of ovarian malignant tumors (Ugianskiene et al., 2014).
Granulosa cell tumor (GCT) is the most common form of ovarian sex-
cord-stromal tumors presenting in two histopathologically different
forms, as common adult granulosa cell tumor (AGCT), and as the less
frequent juvenile granulosa cell tumor (JGCT) (Ugianskiene et al.,
2014; Bryk et al., 2015). In addition to morphological variation, these
two tumor types differ regarding their prognosis and clinical course.
Typically, AGCT are detected at an early stage and often have features
of hyperestrogenism and subsequent menorrhagia and metrorrhagia.
Other presenting symptoms are nonspeciﬁc such as abdominal pain
and swelling. AGCT often follow an indolent course and are character-
ized by a low malignant potential and late relapses (Ugianskiene et al.,
2014; Bryk et al., 2015). Although AGCT has a favorable prognosis
with overall survival rates of 87% and 76% after 5 and 10 years, respec-
tively, (Sehouli et al., 2004) there is a subset of patientswith biologically
aggressive tumors developing recurrence andultimately leading to death.nd Gynecology, Ruhr University
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. This is an open access article underTypically, these recurrences develop late and have been described up to
17 years after the initial diagnosis (Sehouli et al., 2004; Wilson et al.,
2015). There have been efforts to characterize recurrent AGCTs and to
identify prognostic markers associated with recurrence. For example,
initial tumor stage, tumor size, degree of cellular atypia, and mitotic
index have been reported to predict recurrence (Sehouli et al., 2004;
Wilson et al., 2015). In addition, subcellular characteristics such as loss
of ER-beta expression, high proliferating cell nuclear antigen (PCNA)
expression, and aneuploidy have also been described as those features
characterizing the subgroup of AGCT with poor outcome (Staibano
et al., 2003).
Surgery is the mainstay of treatment for the initial management of
women with AGCT with the goal of complete tumor resection
(Ugianskiene et al., 2014; Bryk et al., 2015). There is no established
role for adjuvant chemotherapy or adjuvant hormone therapy
(Gurumurthy et al., 2014). In contrast, systemic chemotherapy is a
commonly used therapy in women with recurrent or primary advanced
AGCT. For example, in a literature review of 15 studies with 224 patients,
van Meurs et al. assessed the response rate to chemotherapy among
women with primary advanced or recurrent AGCT. They calculated a
total response rate (including complete and partial responses) of 50%
(95% conﬁdence interval, 44–57%). Strict criteria of response, however,
were not uniformly applied in the analyzed studies (van Meurs et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Microscopic image of an adult granulosa cell tumor of the ovary. Black bar equals
50 μm (panel A) and 20 μm (panels B and C). Panel A depicts a hematoxylin/eosin staining
of granulosa tumor cells. Panel B depicts an immunohistochemical staining showing
expression of inhibin. Panel C depicts an immunohistochemical staining showing
expression of calretinin.
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Meurs et al. analyzed 22 womenwithmeasurable recurrence or residual
disease treated with hormonal treatment, i.e. tamoxifen or
aromatase inhibitors (van Meurs et al., 2014b). The pooled objective
response rate, deﬁned as complete response or partial response, was
18% (4/22). In one patient (4%) a complete response and in three
(14%) a partial response was described. Fourteen patients (64%)
had stable disease. In the series of Wilson et al., surgery was the main
therapeutic modality at relapse, but 86% of patients additionally received
non-surgical treatments with a clinical beneﬁt rate of 43% for chemo-
therapy, 61% for hormonal therapy and 86% for radiation (Wilson
et al., 2015).
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a form of
local intraperitoneal chemotherapy based on experimental evidence
suggesting an enhanced anti-tumor effect of chemotherapeutic
compounds at an elevated temperature N40 °C (Oseledchyk and
Zivanovic, 2015). Several studies have convincingly shown that
hyperthermia can increase both tumor penetration of cisplatin as well
as DNA crosslinking (Ansaloni et al., 2015). In addition to hyperthermia,
HIPEC theoretically offers a number of further advantages, among them
a high volume of chemotherapy, a homogenous distribution, no interval
between cytoreduction and chemotherapy, high concentrations of
chemotherapy in the intraperitoneal compartment with low systemic
exposure. On the other hand, HIPEC requires intraoperative perfusion
machines, elaborate logistics, and a high degree of organizational effort.
In addition, themorbidity andmortality associated with CRS and HIPEC
are considerable. For example, Voron et al. reported a 2.5% mortality
rate and amajormorbidity rate of 30% in a series of 204 patients treated
with CRS and HIPEC (Voron et al., 2015). Based on the experience
with HIPEC in other tumor entities, this treatment modality has been
proposed for women with recurrent AGCT (Al-Badawi et al., 2014).
The rationale for HIPEC in this indication is the high rate of
intraabdominal tumor recurrence after surgical debulking suggesting
the presence of microscopical residual tumor in many cases. HIPEC is
intended to eradicate these microscopic intraabdominal tumor foci.
We describe the case of a woman with recurrent AGCT, successfully
treated with CRS and HIPEC in our institution.
2. Case report
We present the case of a 60-year-old woman with recurrent AGCT
initially diagnosed 19 years ago. After initial surgery in 1996, the patient
underwent four additional surgical interventions for recurrent disease
in 2005 (abdominal wall), 2009 (abdominal wall), 2010 (paravesical),
and 2011 (paravesical). In 2011, she underwent pelvic irradiation
with 50.5 Gray. In 2015, another recurrence was diagnosed based on
an increase of serum inhibin B and a tumor seen on CT scan in the
right upper abdomen. At laparotomy, the tumor was located attached
to the terminal ileum and the ascending colon. There was no peritoneal
carcinomatosis and no disease in the pelvis or upper abdomen. The
patient underwent cytoreductive surgery (CRS) including a right
hemicolocetomy, resection of the terminal ileum, a side-to-side
(functionally end-to-end) ileotransversostomy, and a subtotal
peritonectomy. A complete cytoreduction with no visible residual
tumor (CCR0) was achieved. Surgery was immediately followed by
HIPEC with cisplatin 50 mg/m2 and doxorubicin 15 mg/m2. We
used a continuous closed circuit abdominal procedure with 5
intraabdominal drains (two for inﬂow and 3 for outﬂow) and two
temperature units in the lower and upper abdomen, respectively,
for temperature monitoring during HIPEC. We used a Belmont®
Hyperthermia Pump (Belmont Instrument Corporation, Billerica,
MA), The duration of HIPECwas 1 hwith an intraabdominal temperature
maintained at 41 °C. Intraabdominal temperatures and the body's core
temperature as well as urinary output were monitored during the
procedure. No intra- or immediate post-operative complications
occurred. On post-operative day 3 the patient reported nausea and
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metoclopramide. No other postoperative complication occurred and
the patient was discharged on postoperative day 6. Final histology
revealed recurrent AGCT with 6 cm in the largest diameter. Fig. 1
shows microscopic images of the tumor including immunohistochemi-
cal studies demonstrating the expression of calretinin and inhibin. After
surgery, antihormonal treatment with anastrozole 1.5 mg per day was
prescribed based on the recommendation of our institutional interdisci-
plinary tumor board.With a follow-up of six months, the patient is well
and alive. Written informed consent for publishing these data was
obtained by the patient.
3. Comment
In this case report, we discuss the clinical course of a patient with
recurrent AGCT treated successfully with CRS and HIPEC. Based on this
case and other reports in the literature (Al-Badawi et al., 2014; Gouy
et al., 2013; Canbay et al., 2012; Hayes-Jordan et al., 2015), we conclude
that CRS and HIPEC in women with recurrent AGCT is feasible and may
be an effective treatment option.
AGCT is a rare entity characterized by high rates of recurrence and
repeated surgical interventions. Although surgery at the time of initial
diagnosis of AGCT is commonly accepted, there is no clear consensus
on the optimal management of women with recurrent disease, which
occurs in a third of patients. For example, in a large retrospective series
of 160 FIGO stage I AGCTs, Wilson et al. observed recurrent disease in
32% (51/160) of cases over a follow-up period of 7 years (Wilson
et al., 2015). The median time to relapse was 12 years underscoring
the typical biological behavior of AGCT with late relapse. Due to the
rarity of AGCT, treatment options for recurrent disease have not been
rigorously tested in clinical trials. Therefore, evidence-based manage-
ment options for recurrent AGCT are limited and treatment options
have not been standardized. In a systematic review of the Cochrane
Collaboration covering the literature until 2014, no comparative trial
in women with recurrent AGCT was identiﬁed (Gurumurthy et al.,
2014). However, in retrospective single-center and multi-center cohort
studies, a variety of treatment options have been described, among them
systemic chemotherapy, surgery, radiation, and hormonal treatment.
Based on the safety and efﬁcacy of CRS and HIPEC in cancer entities
such as colon cancer, gastric cancer, and mesothelioma, CRS and HIPEC
have beenused inwomenwith recurrent AGCT. For example, Al-Badawi
et al. performed CRS and HIPECwith cisplatin (50mg/m2) and doxorubi-
cin (15 mg/m2) in the abdominopelvic cavity for 90 min at 41.0–42.2 °C
(Al-Badawi et al., 2014). Complete cytoreduction was achieved in
all except one patient. Five patients had tumor recurrences in the
abdomen and pelvis and one patient in the abdomen only. No grade V
morbidity according to the Clavien–Dindo classiﬁcation was observed.
Two patients developed lung atelectasis, which was managed by mere
chestphysiotherapy (grade I). One patient developed urinary tract
infection (grade II) and another patient developed pneumonia
(grade II) – both of which were managed by antibiotics. One patient
developed splenic bed and anterior abdominal wall collections
requiring ultrasound-guided aspiration without general anesthesia
(grade III). One patient developed pulmonary embolism requiring
intensive care-unit management (grade IV). These data demonstrate
that CRS followed by HIPEC is feasible in women with recurrent
AGCT. In the absence of controlled comparative trials, it is unclear
whether or not HIPEC has a therapeutic effect in addition to optimal
debulking of recurrent AGCT. However, due to the rarity of this disease,
it is very unlikely that there will ever be large trials comparing various
treatment modalities in the recurrent setting. Therefore, the biologicalrationale of HIPEC treating microscopic tumor foci left behind after
debulking surgery may be used as an argument in favor of this therapy.
In our case report, we found that CRS and HIPEC were feasible and safe
in this situation.
Due to the rarity of recurrent AGCT, there is no consensus regarding
the optimal therapy of this disease. Thus, it is important to identify
additional safe and effective treatment strategies. Based on our case
report and the data reported in the literature we suggest that for
women with recurrent AGCT and disease localized to the abdomen,
CRS and HIPEC may be considered. However, additional literature –
ideally a formal prospective phase II safety and efﬁcacy trial – should
be undertaken, before this treatment can be regarded an accepted
alternative.
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